Sequenom, SensiGen in diagnostics alliance
This article was originally published in Clinica
Executive Summary
Molecular diagnostic specialist Sequenom has agreed to collaborate with biotechnology company SensiGen to develop and commercialise the latter's AttoSense tests. Sequenom will look to integrate Sensigen's assays into its own quantitative gene expression technology and its MassARRAY DNA analysis technology, for detecting diseases including cervical cancer, chronic kidney disease, inflammatory bowel disease and lupus.